ARCT
Price
$5.90
Change
-$0.14 (-2.32%)
Updated
Nov 20, 04:59 PM (EDT)
Capitalization
171.33M
Intraday BUY SELL Signals
PGEN
Price
$3.94
Change
-$0.28 (-6.64%)
Updated
Nov 20, 04:35 PM (EDT)
Capitalization
1.49B
109 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs PGEN

Header iconARCT vs PGEN Comparison
Open Charts ARCT vs PGENBanner chart's image
Arcturus Therapeutics Holdings
Price$5.90
Change-$0.14 (-2.32%)
Volume$37.96K
Capitalization171.33M
Precigen
Price$3.94
Change-$0.28 (-6.64%)
Volume$9.32K
Capitalization1.49B
ARCT vs PGEN Comparison Chart in %
ARCT
Daily Signal:
Gain/Loss:
PGEN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARCT vs. PGEN commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and PGEN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ARCT: $6.03 vs. PGEN: $4.22)
Brand notoriety: ARCT and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 70% vs. PGEN: 98%
Market capitalization -- ARCT: $171.33M vs. PGEN: $1.49B
ARCT [@Biotechnology] is valued at $171.33M. PGEN’s [@Biotechnology] market capitalization is $1.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, PGEN is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 5 TA indicator(s) are bullish while PGEN’s TA Score has 6 bullish TA indicator(s).

  • ARCT’s TA Score: 5 bullish, 5 bearish.
  • PGEN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а -25.83% price change this week, while PGEN (@Biotechnology) price change was +4.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.63%. For the same industry, the average monthly price growth was -6.94%, and the average quarterly price growth was +61.81%.

Reported Earning Dates

PGEN is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (-1.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PGEN($1.49B) has a higher market cap than ARCT($171M). PGEN YTD gains are higher at: 276.339 vs. ARCT (-64.467). ARCT has higher annual earnings (EBITDA): -54.54M vs. PGEN (-121.98M). ARCT has more cash in the bank: 196M vs. PGEN (59.8M). PGEN has less debt than ARCT: PGEN (5.15M) vs ARCT (27M). ARCT has higher revenues than PGEN: ARCT (110M) vs PGEN (4.34M).
ARCTPGENARCT / PGEN
Capitalization171M1.49B11%
EBITDA-54.54M-121.98M45%
Gain YTD-64.467276.339-23%
P/E RatioN/AN/A-
Revenue110M4.34M2,535%
Total Cash196M59.8M328%
Total Debt27M5.15M524%
FUNDAMENTALS RATINGS
ARCT vs PGEN: Fundamental Ratings
ARCT
PGEN
OUTLOOK RATING
1..100
5319
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
9834
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a34

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (55) in the Pharmaceuticals Major industry is in the same range as PGEN (79) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

ARCT's SMR Rating (93) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (34) in the null industry is somewhat better than the same rating for ARCT (98) in the Pharmaceuticals Major industry. This means that PGEN’s stock grew somewhat faster than ARCT’s over the last 12 months.

ARCT's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTPGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signal:
Gain/Loss:
PGEN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JDESX48.720.18
+0.37%
JPMorgan US Research Enhanced Equity I
IEDZX14.02N/A
N/A
Voya Large Cap Value R6
OFVIX21.21N/A
N/A
O'Shaughnessy Market Leaders Value I
BMSTX14.75N/A
N/A
MFS Blended Research Mid Cap Eq R3
JGRRX24.05N/A
N/A
JAG Large Cap Growth R

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-8.91%
ALEC - ARCT
59%
Loosely correlated
-3.54%
AXON - ARCT
49%
Loosely correlated
-0.50%
NEVPF - ARCT
48%
Loosely correlated
N/A
VCYT - ARCT
42%
Loosely correlated
+3.02%
RGNX - ARCT
42%
Loosely correlated
-2.84%
More